A recent commentary by Tseng et al. examines the clinical utility and practical challenges of implementing targeted next-generation sequencing (tNGS) for diagnosing severe pneumonia in ICU settings. While tNGS has demonstrated superior analytical sensitivity compared with conventional microbiological tests (CMTs), its real-world clinical value remains uncertain, particularly in terms of improving patient management and outcomes.
The authors present an interim analysis of an ongoing study conducted at a tertiary medical centre in Taiwan. The study enrolled 51 adult ICU patients with severe pneumonia and compared a hybrid capture–based tNGS platform, the Respiratory Pathogen ID/Antimicrobial Resistance (AMR) Enrichment Panel (RPIP), with standard diagnostic approaches, including CMTs and the FilmArray Pneumonia Panel (FAPP).
Bronchoalveolar lavage (BAL) samples were analysed, and causative pathogens were determined through multidisciplinary expert adjudication integrating clinical, radiological, microbiological, and treatment-response data.
The findings highlight a key distinction between analytical detection and clinically meaningful diagnosis. RPIP achieved a higher analytical detection rate than standard testing (90.2% vs. 82.4%), indicating its ability to identify a broader range of pathogens. However, the proportion of cases in which a causative pathogen was identified was similar between RPIP and standard testing (47.1% vs. 49.0%), with no statistically significant difference. This suggests that increased detection does not necessarily translate into improved clinical relevance.
Further analysis of clinically actionable outcomes revealed mixed benefits. RPIP provided additional clinically actionable information in 23.5% of patients, primarily through detection of antimicrobial resistance determinants. In 17.6% of cases, RPIP and standard testing yielded concordant actionable results, while 13.7% showed lower yield with RPIP. In 45.1% of cases, no causative pathogen was identified even after comprehensive review, underscoring the diagnostic limitations that persist despite advanced technologies.
The study underscores several critical challenges that must be addressed before tNGS can be routinely implemented in ICU practice. First, the optimal timing and patient selection for tNGS remain unclear. In approximately one-third of cases, tNGS provided no additional or even less information than standard testing, suggesting that existing methods may suffice for many patients. Given the high cost of tNGS, its use must be carefully targeted, potentially focusing on specific populations such as immunocompromised patients, although evidence in this subgroup remains conflicting.
Second, the clinical application of AMR data generated by tNGS is currently limited. Although platforms like RPIP can detect a large number of resistance genes, discrepancies between genotypic resistance markers and actual phenotypic susceptibility are common. This limits the reliability of using tNGS data alone to guide antimicrobial therapy. Robust validation of genotype–phenotype correlations and an understanding of local resistance patterns are essential before such data can be routinely used in clinical decision-making.
Third, the authors emphasise the importance of recognising non-infectious conditions that can mimic pneumonia. The high proportion of cases without an identified pathogen suggests that some patients may have inflammatory or immune-mediated lung diseases rather than infections. In such scenarios, tNGS could support antimicrobial stewardship by helping clinicians avoid unnecessary broad-spectrum antibiotic use. However, real-world studies indicate that antimicrobial therapy is often unchanged despite molecular diagnostic results, possibly due to clinician uncertainty or the severity of illness in ICU patients. Multidisciplinary evaluation of results, particularly negative findings, is crucial.
Fourth, significant laboratory and workflow challenges must be overcome. Sample collection from non-sterile sites such as BAL requires strict standardisation to minimise contamination. Background microbial signals may arise from reagents, laboratory environments, or procedural variability, complicating interpretation. The study also highlights the importance of optimising turnaround time (TAT). In this cohort, the median TAT for tNGS was 6.5 days, limiting its utility as a real-time clinical tool and positioning it instead as an adjunctive diagnostic method. In contrast, other studies have demonstrated much shorter TATs, suggesting that workflow optimisation and infrastructure are critical determinants of clinical usefulness.
Bioinformatic analysis represents another major barrier. Accurate interpretation of sequencing data requires sophisticated pipelines capable of distinguishing true pathogens from colonisers or contaminants. The authors describe the use of a rule-based stratification approach incorporating metrics such as read depth and abundance, calibrated against local data to reduce false-positive results. However, standardising and scaling such approaches across institutions remains challenging.
The commentary outlines key considerations for implementing tNGS in clinical practice, including defining clear indications, standardising workflows, ensuring quality control, integrating results with clinical context, and establishing multidisciplinary review processes. Effective governance and continuous validation are essential to ensure reliable and clinically meaningful use.
In conclusion, while tNGS offers significant potential to enhance pathogen detection and reduce diagnostic uncertainty in severe pneumonia, its routine deployment in ICUs is not yet fully justified. The technology’s clinical impact depends not only on its diagnostic capabilities but also on appropriate patient selection, rapid and reliable workflows, accurate interpretation, and integration into clinical decision-making frameworks. Future research should prioritise demonstrating improvements in patient outcomes and antimicrobial stewardship rather than focusing solely on diagnostic yield.
Source: Critical Care
Image Credit: iStock
